NovaBridge Biosciences (NBP) vs Minerva Neurosciences (NERV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Minerva Neurosciences (NERV) has outperformed NovaBridge Biosciences (NBP) over the past year, gaining 13.8% versus a loss of 73.0%. Over five years, NERV leads with a -69.7% price change compared with -97.9% for NBP. NovaBridge Biosciences is the larger company by market cap ($158.9 million vs $153.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NBP | NERV |
|---|---|---|
| Share price | $1.37 | $3.22 |
| Market cap | $158.92M | $153.75M |
| 1-day change | 0.00% | -1.53% |
| YTD return | -65.58% | -19.90% |
| 1-year return | -72.98% | +13.78% |
| 5-year return | -97.92% | -69.72% |
| EPS (TTM) | $-0.69 | $-36.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.79 | $12.46 |
| 52-week low | $1.31 | $2.24 |
| Distance from 52-week high | -79.82% | -74.16% |
| Analyst consensus | none | none |
| Avg. price target upside | +556.93% | +220.81% |
| Average volume | 382.99K | 183.63K |
| Shares outstanding | 116.00M | 47.75M |
| Employees | 30 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NERV has outperformed NBP by 86.8 percentage points over the past year.
About NovaBridge Biosciences
NBP stock →NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology.
Health Care · Biotechnology: Pharmaceutical Preparations · 30 employees
About Minerva Neurosciences
NERV stock →Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
NBP vs NERV FAQ
Which is bigger, NovaBridge Biosciences or Minerva Neurosciences?
NovaBridge Biosciences (NBP) is larger, with a market capitalization of $158.92M compared with $153.75M for Minerva Neurosciences (NERV).
Which stock has performed better over the past year, NBP or NERV?
NERV returned +13.78% over the past 12 months, compared with -72.98% for NBP (price return, excluding dividends). Past performance does not predict future results.
Are NovaBridge Biosciences and Minerva Neurosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.